A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

ROWLEY, JANET D.·1973·Nature
DOI 10.1038/243290a0

Cited by (1,005)

Items 901–1,000 of 1,005

  1. A Roadmap Toward the Definition of Actionable Tumor-Specific Antigens
    Robin Minati, Claude Perreault, Pierre Thibault · 2020 · Frontiers in Immunology
  2. B-cell–specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs
    Takuya Kamio, Tsutomu Toki, Rika Kanezaki, Shinya Sasaki, Satoru Tandai, Kiminori Terui, Dai Ikebe, Kazuhiko Igarashi, Etsuro Ito · 2003 · Blood
  3. Clinical Applications of BCR-ABL Molecular Testing in Acute Leukemia
    Amgad L. Nashed, Kathleen W. Rao, Margaret L. Gulley · 2003 · Journal of Molecular Diagnostics
  4. Genomic Mechanisms of p210BCR-ABL Signaling
    Sutapa Ray, Ying Chun Lu, Scott H. Kaufmann, William Clay Gustafson, Judith E. Karp, Istvan R. Boldogh, Alan P. Fields, Allan R. Brasier · 2004 · Journal of Biological Chemistry
  5. Classical Hodgkin lymphoma is associated with frequent gains of 17q
    Daniel T.Y. Chui, David W. Hammond, Margaret Baird, Lesley A. Shield, Robert Jackson, Ruth F. Jarrett · 2003 · Genes Chromosomes and Cancer
  6. Comparison of constitutional and tumor-associated 11;22 translocations: nonidentical breakpoints on chromosomes 11 and 22.
    Chandi A Griffin, C McKeon, Mark A. Israel, Anne Gégonne, Jacques Ghysdael, D. Stéhelin, E C Douglass, Audrey Green, Beverly S. Emanuel · 1986 · Proceedings of the National Academy of Sciences
  7. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1
    Ayalew Tefferi · 2009 · Journal of Cellular and Molecular Medicine
  8. Synthetic tumor‐specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease
    Nitin Jain, James Mwikya Reuben, Hagop M. Kantarjian, Changping Li, Hui Gao, Bang-Ning Lee, Evan N. Cohen, Theresa Ebarb, David A. Scheinberg, Jörge E. Cortes · 2009 · Cancer
  9. Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer
    Yu‐Wei Cheng, Kamran Idrees, Richard Shattock, Sajid Ali Khan, Zhaoshi Zeng, Cameron Walter Brennan, Philip B. Paty, Francis Barany · 2009 · International Journal of Cancer
  10. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients
    Dolly Joshi, S. Chandrakala, Seema A. Korgaonkar, Kanjaksha Ghosh, Babu Rao Vundinti · 2014 · Gene
  11. What are we learning from the cancer genome?
    Eric A. Collisson, Raymond Jaihyun Cho, Joe W. Gray · 2012 · Nature Reviews Clinical Oncology
  12. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
    Kendra Lynn Sweet, Lori Hazlehurst, Eva Sahakian, John Joseph Powers, Lisa Nodzon, Fadi Kayali, Kelly A. Hyland, Ashley M. Nelson, Javier A. Pinilla-Ibarz · 2018 · Leukemia Research
  13. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
    Donal P. McLornan, Melanie J. Percy, Mary Frances McMullin · 2006 · PubMed Central
  14. Human chromosome 22.
    Kaplan Jc, Alain Aurias, Cécile Julier, M Prieur, Marie‐France Szajnert · 1987 · Journal of Medical Genetics
  15. Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML
    Stéphanie Salesse, Catherine M. Verfaillie · 2002 · Oncogene
  16. Lymphocyte Surface Immunoglobulins in Hodgkin's Disease
    P Gergely, G Szegedi, E Berényi, G Petrányi · 1973 · New England Journal of Medicine
  17. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells
    Roger R. Beerli, C Issaad, Marc J. Pallardy, MC Leglise, Ali G. Turhan, Jacques H. Bertoglio, J Bréard · 1996 · Blood
  18. Restricted oncogenicity of BCR/ABL p190 in transgenic mice.
    Jan Willem Voncken, S Griffiths, Melvyn F. Greaves, P K Pattengale, Nora Heisterkamp, John Groffen · 1992 · PubMed
  19. Variable breakpoints on the Philadelphia chromosome in chronic myelogenous leukemia
    David S. Leibowitz, K E Schaefer-Rego, DW Popenoe, JG Mears, A Bank · 1985 · Blood
  20. Chromosome pattern, growth in agar and tumorigenicity in nude mice of four human bladder carcinoma cell lines
    R. J. Hastings, L. M. Franks · 1981 · International Journal of Cancer
  21. The cytogenetics of acute leukaemia
    Janet D. Rowley · 1978 · Clinics in Haematology
  22. The BCL-2 protein family: from discovery to drug development
    Carlo Maria Croce, David Lawrence Vaux, Andreas Strasser, Joseph T. Opferman, Peter E. Czabotar, Stephen W. Fesik · 2025 · Cell Death and Differentiation
  23. Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays
    Ayda Bennour, Ali Saad, Halima Sennana · 2015 · Critical Reviews in Oncology/Hematology
  24. Identification of Basophils as a Major Source of Hepatocyte Growth Factor in Chronic Myeloid Leukemia: A Novel Mechanism of BCR-ABL1-Independent Disease Progression
    Sabine Cerny‐Reiterer, Viviane Ghanim, Gregor Hoermann, Karl J. Aichberger, Harald Herrmann, Leonhard Müllauer, Andreas Repa, Christian Sillaber, Andrew F. Walls, Matthias Mayerhofer et al. · 2012 · Neoplasia
  25. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study
    Franck Emmanuel Nicolini, Gabriel Étienne, Viviane Dubruille, Lydia Roy, Françoise Huguet, Laurence Legros, Stéphane Giraudier, Valérie Coiteux, Agnès Guerci‐Bresler, Pascal Lenain et al. · 2015 · The Lancet Haematology
  26. Molecular biology of chronic myeloid leukemia
    Yoshiro Maru · 2012 · Cancer Science
  27. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B‐lymphoblastic leukemia in the era of tyrosine kinase inhibitors
    Jesse Manuel Jaso, Deborah Ann Thomas, Krista Cunningham, Jeffrey L. Jorgensen, Hagop M. Kantarjian, Leonard Jeffrey Medeiros, Sa A. Wang · 2011 · Cancer
  28. Why imatinib remains an exception of cancer research
    Steven D. Horne, Joshua B. Stevens, Batoul Y. Abdallah, Guo Liu, Steven W. Bremer, Christine J. Ye, Henry H. Heng · 2012 · Journal of Cellular Physiology
  29. Snaps and mends: DNA breaks and chromosomal translocations
    Saniya M. Javadekar, Sathees C. Raghavan · 2015 · FEBS Journal
  30. Clinical Implementation of Comprehensive Strategies to Characterize Cancer Genomes: Opportunities and Challenges
    Laura E. MacConaill, Paul Van Hummelen, Matthew M. Meyerson, William C. Hahn · 2011 · Cancer Discovery
  31. Development of an Integrated Assay for Detection of BCR-ABL RNA
    Emily S. Winn-Deen, Bret Helton, Reuel Van Atta, Wendy Wong, Jeffrey Peralta, James Wang, Gregory J. Tsongalis, Dorothy R. Belloni, David W. Chan, James R. Eshleman et al. · 2007 · Clinical Chemistry
  32. Allogeneic transplantation for CML in the TKI era: striking the right balance
    Andrew J. Innes, Dragana Milojković, Jane F. Apperley · 2015 · Nature Reviews Clinical Oncology
  33. Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
    Ziyuan Lu, Na Xu, Bolin He, Chengyun Pan, Yangqing Lan, Hongsheng Zhou, Xiaoli Liu · 2017 · Journal of Experimental & Clinical Cancer Research
  34. Contribution of fluorescence in situ hybridization analyses to the characterization of masked and complex Philadelphia chromosome translocations in chronic myelocytic leukemia
    Fréderic Morel, Angèle Herry, M.‐J. Le Bris, Patrick Morice, P Bouquard, J.F. Abgrall, Christian Berthou, Marc De Braekeleer · 2003 · Cancer Genetics and Cytogenetics
  35. c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia
    Barbara Anne Jennings, Ken Mills · 1998 · Leukemia Research
  36. Treatment selection after imatinib resistance in chronic myeloid leukemia
    Elias Joseph Jabbour, Jörge E. Cortes, Hagop M. Kantarjian · 2009 · Targeted Oncology
  37. The Philadelphia chromosome
    Takaaki Ishihara, Masako Minamihisamatsu · 1988 · Cancer Genetics and Cytogenetics
  38. Karyotypic analysis and chromosome polymorphisms in four choriocarcinoma cell lines
    David M. Sheppard, Rosemary Ann Fisher, Sylvia D. Lawler · 1985 · Cancer Genetics and Cytogenetics
  39. Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines
    Philippe Martiat, Philippe Lewalle, A. S. Taj, M Philippe, Yvan Larondelle, Jl. Vaerman, Claude Wildmann, John M. Goldman, Jl. Michaux · 1993 · Blood
  40. Histological and cytogenetic findings in a malignant tumor of the chest wall and lung (Askin tumor)
    Thomas A. Seemayer, Michel J. J. Vekemans, Jean-Pierre Chadar�vian · 1985 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  41. Chronic myeloid leukemia with permanent disappearance of the Ph1 chromosome and development of new clonal subpopulations
    A Hagemeijer, EM Smit, B Lowenberg, Johannes Abels · 1979 · Blood
  42. The first BCR gene intron contains breakpoints in Philadelphla chromosome positive leukemia
    Nora Heisterkamp, Eva Knoppel, John Groffen · 1988 · Nucleic Acids Research
  43. Advances in Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: The Evolving Role of Bcr–Abl Mutations and Mutational Analysis
    Simona Soverini, Giovanni Martinelli, Gianantonio Rosti, Ilaria Iacobucci, Michele Baccarani · 2012 · Pharmacogenomics
  44. Chimeric RNAs in cancer
    Xinrui Shi, Sandeep Singh, Emily Lin, Hui Li · 2020 · Advances in clinical chemistry
  45. Overview of Myeloproliferative Neoplasms
    Douglas A. Tremblay, Abdulraheem Yacoub, Ronald Hoffman · 2021 · Hematology/Oncology Clinics of North America
  46. The oncogenic fusion landscape in pediatric CNS neoplasms
    Mieke M Roosen, Zelda Odé, Jens Bunt, Marcel Kool · 2022 · Acta Neuropathologica
  47. An Overview of Targeted Therapies in Acute Myeloid Leukemia
    Sven Turkalj, Felix A. Radtke, Paresh Vyas · 2023 · HemaSphere
  48. Role of Epigenetics in Chronic Myeloid Leukemia
    Kateřina Machová Poláková, Jitka Koblihova, Tomáš Stopka · 2013 · Current Hematologic Malignancy Reports
  49. Cancer mouse models: Past, present and future
    Walid T. Khaled, Pentao Liu · 2014 · Seminars in Cell and Developmental Biology
  50. Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia
    Huilin Huang, Hengyou Weng, Bowen Dong, Panpan Zhao, Hui Zhou, Liang‐Hu Qu · 2017 · Scientific Reports
  51. Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
    Norihito Shibata, Kenichiro Shimokawa, Katsunori Nagai, Nobumichi Ohoka, Takayuki Hattori, Naoki Miyamoto, Osamu Ujikawa, Tomoya Sameshima, Hiroshi Nara, Nobuo Cho et al. · 2018 · Scientific Reports
  52. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells.
    Nilamani Jena, Ming Deng, Eva Sicinska, Piotr Siciński, George Q. Daley · 2002 · PubMed
  53. Analysis of Bcr‐Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P‐loop and T315I mutation is disease phase dependent
    Soo‐Hyun Kim, Dong‐Ho Kim, Dong‐Wook Kim, Hyun‐Gyung Goh, Se‐Eun Jang, Jeong Eon Lee, Wan‐Seok Kim, Il‐Young Kweon, Sa-Hee Park · 2009 · Hematological Oncology
  54. How I manage priapism in chronic myeloid leukaemia patients
    Ryan Rodgers, Zak Latif, Mhairi Copland · 2012 · British Journal of Haematology
  55. Biology of BCR-ABL
    Rajesh Chopra, Q.Q Pu, Andrew G. Elefanty · 1999 · Blood Reviews
  56. Targeted therapies in myeloid leukemia
    A M John, Nicholas Shaun B. Thomas, Ghulam Jeelani Mufti, Rose Ann Padua · 2004 · Seminars in Cancer Biology
  57. Comparable complex rearrangements involving 8;21 and 9;22 translocations in leukaemia
    Valerie Lindgren, Janet D. Rowley · 1977 · Nature
  58. Structural variability of human chromosome 9 in relation to its evolution
    Ingo Hansmann · 1976 · Human Genetics
  59. Application of chromosome microdissection probes for elucidation of BCR- ABL fusion and variant Philadelphia chromosome translocations in chronic myelogenous leukemia
    J Zhang, Paul S. Meltzer, Robert Brian Jenkins, Xin‐Yuan Guan, Jeffrey M. Trent · 1993 · Blood
  60. Karyotype patterns in human meningiomas
    Joachim Mark · 2009 · Hereditas
  61. B-lymphoid cell involvement in chronic myelogenous leukemia: Implications for the pathogenesis of the disease
    Paul J. Martin, Vesna Najfeld, Philip J. Fialkow · 1982 · Cancer Genetics and Cytogenetics
  62. Chromosome abnormalities in patients with hairy cell leukemia
    Harvey M. Golomb, Valerie Lindgren, Janet D. Rowley · 1978 · Cancer
  63. Inhibition of Grb2 expression demonstrates an important role in BCR–ABL-mediated MAPK activation and transformation of primary human hematopoietic cells
    Hardik Modi, Lushen Li, S. Haihua Chu, John J. Rossi, J-K Yee, Ravi Bhatia · 2010 · Leukemia
  64. Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
    Ahmad Hamad, Zeyad T. Sahli, Maya El Sabban, Maha Mouteirik, Rihab Nasr · 2013 · Stem Cells International
  65. A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell
    Keisuke Ito, Rosa Bernardi, Pier Paolo Pandolfi · 2009 · Current Opinion in Genetics & Development
  66. Human leukemic cell lines synthesize hyaluronan to avoid senescence and resist chemotherapy
    Silvina Laura Lompardía, Daniela Laura Papademetrio, M. Mascaro, E. M. d. C. Alvarez, S. E. HAJOS · 2013 · Glycobiology
  67. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
    Marjan Yaghmaie, Seyed Hamidollah Ghaffari, Ardashir Ghavamzadeh, K. Alimoghaddam, Mohammad Mehdi Jahani, Seyed-Asadollah Mousavi, Masoud Irvani, Babak Bahar, Isa Bibordi · 2008 · PubMed
  68. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells
    Stéphanie Salesse, Scott J. Dylla, Catherine M. Verfaillie · 2004 · Leukemia
  69. JAK2 V617F in myeloid disorders: What do we know now, and where are we headed?
    Maria E. Nelson, David P. Steensma · 2005 · Leukemia & lymphoma/Leukemia and lymphoma
  70. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation
    Sharmila Prabhu, D Saadat, Maggie Zhang, L Halbur, John P. Fruehauf, S. Tiong Ong · 2006 · Oncogene
  71. Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: Characterization of the apoptotic death
    Anne J. McGahon, David G. Brown, Séamus J. Martin, Gustavo Pessini Amarante-Mendes, Thomas G. Cotter, Gerald M. Cohen, Douglas R. Green · 1997 · Cell Death and Differentiation
  72. Cancer Markers of the 1990s: Comparison of the New Generation of Markers Defined by Monoclonal Antibodies and Oncogene Probes to Prototypic Markers
    Stewart Sell · 1990 · Clinics in Laboratory Medicine
  73. Deletion of the 5′‐ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia‐positive chronic myeloid leukaemia patients
    Christian Herens, F. Tassin, V. Lemaire, Yves P. Beguin, E. Collard, S. Lampertz, Christiane Croisiau, Marianne Lecomte, B. De Prijk, L. Longrée et al. · 2000 · British Journal of Haematology
  74. Runx1/AML1 in leukemia: disrupted association with diverse protein partners
    Chava Perry, Amiram Eldor, Hermona Soreq · 2002 · Leukemia Research
  75. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia
    John M. Goldman · 2000 · The Lancet
  76. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
    Hagop M. Kantarjian, Moshe Talpaz, Michael J. Keating, Elihu H. Estey, Susan Mary O'Brien, Miloslav Beran, KENNETH B. McCREDIE, J. U. Gutterman, Emil J. Freireich · 1991 · Cancer
  77. Two complex translocations in chronic granulocytic leukemia involving chromosomes 22, 9, and a third chromosome
    Peter C. Nowell̀, Julie Jensen, Frank H. Gardner · 1975 · Human Genetics
  78. CML vaccines as a paradigm of the specific immunotherapy of cancer
    Javier A. Pinilla-Ibarz, Kathleen N. S. Cathcart, David A. Scheinberg · 2000 · Blood Reviews
  79. The Philadelphia chromosome: A model of cancer and molecular cytogenetics
    Avery A. Sandberg, Robert M. Gemmill, Barbara K. Hecht, Frederick Hecht · 1986 · Cancer Genetics and Cytogenetics
  80. Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study
    Jost Klawitter, Nora Anderson, Jost Klawitter, Uwe Christians, Dieter Leibfritz, Sabine Eckhardt, Natalie J. Serkova · 2009 · British Journal of Cancer
  81. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy
    Mohamed A. M. Ali · 2016 · Molecular Diagnosis & Therapy
  82. Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase
    Xiaohui Chang, Lin Zhou, Xiaoxia Chen, Baoli Xu, Yubin Cheng, Shujun Sun, Meiyun Fang, Yang Xiang · 2017 · Targeted Oncology
  83. Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making
    James A. Kennedy, Gabriela Soriano Hobbs · 2018 · Current Hematologic Malignancy Reports
  84. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
    Ming-Chin Chang, Hung-I Cheng, Kate Hsu, Yen-Ning Hsu, Chen-Wei Kao, Yi‐Fang Chang, Ken‐Hong Lim, Caleb Gon‐Shen Chen · 2019 · Frontiers in Immunology
  85. Influence of Bone Marrow Microenvironment on Leukemic Stem Cells
    Puneet Agarwal, Ravi Bhatia · 2015 · Advances in cancer research
  86. Philadelphia chromosome‐positive acute lymphoblastic leukemia– current concepts and future perspectives
    Stefan Faderl, Guillermo Garcia‐Manero, Deborah Ann Thomas, Hagop M. Kantarjian · 2002 · Reviews in Clinical and Experimental Hematology
  87. Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-α, -β, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy
    Christine Haberler, Ellen Gelpí, Christine Marosi, Karl Rössler, P. Birner, Herbert Budka, Johannes Andreas Hainfellner · 2005 · Journal of Neuro-Oncology
  88. Role of abnormal integrin-cytoskeletal interactions in impaired β1 integrin function in chronic myelogenous leukemia hematopoietic progenitors
    Ravi Bhatia, Heidi A. Munthe, Catherine M. Verfaillie · 1999 · Experimental Hematology
  89. t(5;12)(q31;p12) A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia
    J.W. Wessels, Willem E. Fibbe, D. van der Keur, James E. Landegent, D. C. van der Plas, Gerard J. Den Ottolander, Klaas J. Roozendaal, G.C. Beverstock · 1993 · Cancer Genetics and Cytogenetics
  90. Adult T-cell leukemia. Chromosome analysis of 15 cases
    Kanji Miyamoto, Jiro Sato, Koichi Kitajima, Atushi Togawa, Shuso Suemaru, Hiroshi Sanada, Toshio Tanaka · 1983 · Cancer
  91. In vitro effects of STI 571‐containing drug combinations on the growth of Philadelphia‐positive chronic myelogenous leukemia cells
    Barbara Scappini, Francesco Onida, Hagop M. Kantarjian, Li Dong, Srđan Verstovšek, Michael J. Keating, Miloslav Beran · 2002 · Cancer
  92. bcr rearrangement in Ph-negative CML
    Claus Rainer Bartram, Felix Carbonell · 1986 · Cancer Genetics and Cytogenetics
  93. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells
    F. Pellicanò, Pavel Šimara, Anne E. Sinclair, G. Vignir Helgason, Mhairi Copland, Steven Grant, Tessa L. Holyoake · 2011 · Leukemia
  94. Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?
    Simona Soverini, Gianantonio Rosti, Ilaria Iacobucci, Michele Baccarani, Giovanni Martinelli · 2011 · The Oncologist
  95. N‐[2‐Methyl‐5‐(triazol‐1‐yl)phenyl]pyrimidin‐2‐amine as a Scaffold for the Synthesis of Inhibitors of Bcr‐Abl
    Federica Arioli, Stella Borrelli, Francesco Colombo, Federico Falchi, Irene Filippi, Emmanuele Crespan, Antonella Naldini, Giusy Scalia, Alessandra Silvani, Giovanni Maga et al. · 2011 · ChemMedChem
  96. Do we need more drugs for chronic myeloid leukemia?
    Tessa L. Holyoake, G. Vignir Helgason · 2014 · Immunological Reviews
  97. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).
    Martin Henkes, Heiko van der Kuip, Walter E. Aulitzky · 2008 · PubMed Central
  98. 9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation
    Wei‐Sheng Huang, Xiaotian Zhu, Yihan Wang, Mohammad Azam, David J. Wen, Raji Sundaramoorthi, Royston M. Thomas, Shuangying Liu, Geetha Banda, Scott P. Lentini et al. · 2009 · Journal of Medicinal Chemistry
  99. CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl–expressing cells
    Jennifer Rhodes, Randall D. York, David Tara, Katsu Tajinda, Brian J. Druker · 2000 · Experimental Hematology
  100. Quantification of change in phosphorylation of BCR‐ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells
    Xiquan Liang, Mahbod Hajivandi, Darren R. Veach, David John Wisniewski, Bayard D. Clarkson, Marilyn D. Resh, R. Marshall Pope · 2006 · PROTEOMICS